Influenza Clinical Trial Drug Development Pipeline Expands with 120+ Companies
A report published in October 2026 details over 120 companies and 120 drug development projects in the influenza treatment landscape.
New Report: Influenza Drug Development Active Across Over 120 Companies
Albany, US – October 2026 – DelveInsight's "Influenza Pipeline Insight 2026" report reveals that more than 120 companies are actively developing new influenza treatments. The report covers over 120 drug development projects, including those in clinical and preclinical stages.
The analysis provides a comprehensive overview of the current state of influenza drug development, examining various drug types, development stages, routes of administration, and molecule types. It also identifies discontinued or inactive development projects in the field.
Recent advancements, such as ENA Respiratory initiating Phase IIa study for its INNA-051 nasal spray and GSK's plans to advance its mRNA seasonal influenza vaccine candidate into Phase III trials following positive results, indicate ongoing activity.
According to DelveInsight, there is a significant need for new, more effective therapies in influenza treatment. Influenza remains a contagious respiratory illness that causes substantial morbidity, mortality, and economic losses. The report aims to offer in-depth information on the challenges and opportunities within drug development for this disease.